Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Tyrosine Protein Kinase JAK3 pipeline market research report provides comprehensive information on the Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects.
Key MoA in the Tyrosine Protein Kinase JAK3 Pipeline Market
The key MoA in the Tyrosine Protein Kinase JAK3 pipeline market is Tyrosine Protein Kinase JAK3 Inhibitor.
Key RoA in the Tyrosine Protein Kinase JAK3 Pipeline Market
The key RoA in the Tyrosine Protein Kinase JAK3 pipeline market are oral, topical, ophthalmic, cutaneous, and inhalational. Oral has the highest pipeline market.
Tyrosine Protein Kinase JAK3 Pipeline Market, by RoA
For more RoA insights, download a free report sample
Key Molecule Type in the Tyrosine Protein Kinase JAK3 Pipeline Market
The key molecule type in the Tyrosine Protein Kinase JAK3 pipeline market is small molecule.
Key Companies in the Tyrosine Protein Kinase JAK3 Pipeline Market
The key companies in the Tyrosine Protein Kinase JAK3 pipeline market are Aclaris Therapeutics Inc, Alexion Pharmaceuticals Inc, Arrien Pharmaceuticals LLC, Astellas Pharma Inc, Bristol-Myers Squibb Co, Celon Pharma SA, Clevexel Pharma SA, and Daewoong Pharmaceutical Co Ltd. Aclaris Therapeutics Inc has the highest pipeline products.
Tyrosine Protein Kinase JAK3 Pipeline Market, by Companies
To know about more companies, download a free report sample
Market report overview
Key MoA | Tyrosine Protein Kinase JAK3 Inhibitor |
Key RoA | Oral, Topical, Ophthalmic, Cutaneous, and Inhalational |
Key molecule type | Small Molecule |
Key companies | Aclaris Therapeutics Inc, Alexion Pharmaceuticals Inc, Arrien Pharmaceuticals LLC, Astellas Pharma Inc, Bristol-Myers Squibb Co, Celon Pharma SA, Clevexel Pharma SA, and Daewoong Pharmaceutical Co Ltd |
Scope
- The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2)
- The report reviews Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Alexion Pharmaceuticals Inc
Arrien Pharmaceuticals LLC
Astellas Pharma Inc
Bristol-Myers Squibb Co
Celon Pharma SA
Clevexel Pharma SA
Daewoong Pharmaceutical Co Ltd
Guangdong Zhongsheng Pharmaceutical Co Ltd
Impetis Biosciences Ltd
Japan Tobacco Inc
KBP Biosciences Co Ltd
Kinaset Therapeutics Inc
MedAvail Holdings Inc
Merck & Co Inc
Oncostellae SL
Pfizer Inc
Shenzhen Chipscreen Biosciences Co Ltd
Simcere Pharmaceutical Group Ltd
Theravance Biopharma Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key MoA in the Tyrosine Protein Kinase JAK3 pipeline market?
The key MoA in the Tyrosine Protein Kinase JAK3 pipeline market is Tyrosine Protein Kinase JAK3 Inhibitor.
-
What are the key RoA in the Tyrosine Protein Kinase JAK3 pipeline market?
The key RoA in the Tyrosine Protein Kinase JAK3 pipeline market are oral, topical, ophthalmic, cutaneous, and inhalational.
-
What are the key molecule type in the Tyrosine Protein Kinase JAK3 pipeline market?
The key molecule type in the Tyrosine Protein Kinase JAK3 pipeline market is small molecule.
-
What are the key companies in the Tyrosine Protein Kinase JAK3 pipeline market?
The key companies in the Tyrosine Protein Kinase JAK3 pipeline market are Aclaris Therapeutics Inc, Alexion Pharmaceuticals Inc, Arrien Pharmaceuticals LLC, Astellas Pharma Inc, Bristol-Myers Squibb Co, Celon Pharma SA, Clevexel Pharma SA, and Daewoong Pharmaceutical Co Ltd.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.